As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.